Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels

Tumor microvessels differ in structure and metabolic function from normal vasculature, and neoangiogenesis is associated with quantitative and qualitative changes in expression of endothelial proteins. Such molecules could serve as molecular addresses differentiating the tumor vasculature from those of the normal brain. We have applied Systematic Evolution ofLigands by EXponential enrichment (SELEX) against transformed endothelial cells as a complex target to select single-stranded DNA-ligands (aptamers) that function as histological markers to detect microvessels of rat experimental glioma, a fatal brain tumor that is highly vascularized. Both the SELEX selection procedure as well as subsequent deconvolution-SELEX were analyzed by fluorescence based methods (flow cytometry and fluorescence microscopy). Of 25 aptamers analyzed, one aptamer was selected that selectively bound microvessels of rat brain glioblastoma but not the vasculature of the normal rat brain including peritumoral areas. The molecular target protein of aptamer III.1 was isolated from endothelial cells by ligand-mediated magnetic DNA affinity purification. This protein was identified by mass spectrometry as rat homologue of mouse pigpen, a not widely known endothelial protein the expression of which parallels the transition from quiescent to angiogenic phenotypesin vitro. Because neoangiogenesis, the formation of new blood vessels, is a key feature of tumor development, the presented aptamer can be used as a probe to analyze pathological angiogenesis of glioblastoma. The presented data show that pigpen is highly expressed in tumor microvessels of experimental rat brain glioblastoma and may play an important role in warranting blood supply, thus growth of brain tumors.

[1]  M. C. Alliegro.  A C-terminal carbohydrate-binding domain in the endothelial cell regulatory protein, pigpen: new function for an EWS family member. , 2000, Experimental cell research.

[2]  Vicki Brower,et al.  Tumor angiogenesis—new drugs on the block , 1999, Nature Biotechnology.

[3]  Dario Neri,et al.  Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment , 1999, Nature Biotechnology.

[4]  S D Jayasena,et al.  Staining of cell surface human CD4 with 2'-F-pyrimidine-containing RNA aptamers for flow cytometry. , 1998, Nucleic acids research.

[5]  A. Pines,et al.  High-resolution 27AI NMR spectroscopy of the aluminophosphate molecular sieve VPI-5 , 1990, Nature.

[6]  A. Varki,et al.  DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. , 1996, The Journal of clinical investigation.

[7]  L. Zardi,et al.  Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.

[8]  A D Ellington,et al.  In vitro selection of nucleic acid aptamers that bind proteins. , 1996, Methods in enzymology.

[9]  K. Plate.  Mechanisms of angiogenesis in the brain. , 1999, Journal of neuropathology and experimental neurology.

[10]  S D Jayasena,et al.  Use of a high affinity DNA ligand in flow cytometry. , 1996, Nucleic acids research.

[11]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[12]  P. Thorpe,et al.  Targeting the vasculature of solid tumors , 1993 .

[13]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[14]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[15]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[16]  M. Alliegro,et al.  A nuclear protein regulated during the transition from active to quiescent phenotype in cultured endothelial cells. , 1996, Developmental biology.

[17]  P. Kristjansen,et al.  Tumor angiogenesis ‐ a new therapeutic target in gliomas , 1998, Acta neurologica Scandinavica.

[18]  B. Zetter.  On target with tumor blood vessel markers , 1997, Nature Biotechnology.

[19]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[20]  J. Wills,et al.  Isolation of virus-neutralizing RNAs from a large pool of random sequences. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[22]  A. Crameri,et al.  10(20)-fold aptamer library amplification without gel purification. , 1993, Nucleic acids research.

[23]  L. Gold,et al.  High affinity ligands from in vitro selection: complex targets. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Dario Neri,et al.  Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.

[25]  F. Di Virgilio,et al.  Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. , 1996, Journal of immunology.

[26]  T. Fitzwater,et al.  A SELEX primer. , 1996, Methods in enzymology.

[27]  Enrico A. Stura,et al.  Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å , 1996, Science.

[28]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[29]  L. Lampson,et al.  Disseminating tumor cells and their interactions with leukocytes visualized in the brain. , 1992, Cancer research.

[30]  M. Gleichmann,et al.  Both the Neuronal and Inducible Isoforms Contribute to Upregulation of Retinal Nitric Oxide Synthase Activity by Brain-Derived Neurotrophic Factor , 1999, The Journal of Neuroscience.

[31]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[32]  C. Koch,et al.  Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.

[33]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[34]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .